CMMB (Chemomab Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


CMMB Chemomab Therapeutics Ltd CMMB
33 GF Score
Price $1.59
View Full Analysis

What is Chemomab Therapeutics EBITDA Margin %?

Chemomab Therapeutics CMMB 33 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates CMMB with a GF Score™ of 33/100. Among 944 Biotechnology companies, Chemomab Therapeutics ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Chemomab Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-1.85 Mil. Chemomab Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Chemomab Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Chemomab Therapeutics  (NAS:CMMB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Chemomab Therapeutics EBITDA Margin % Related Terms

Chemomab Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Chemomab Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics EBITDA Margin % Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Chemomab Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CMMB vs HCWB, MTVA, INTI: EBITDA Margin % Comparison

For the Biotechnology subindustry, Chemomab Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's EBITDA Margin % falls into.


CMMB
33GF Score
Chemomab Therapeutics Ltd CMMB
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemomab Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Chemomab Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-9.497/0
= %

Chemomab Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.85/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Chemomab Therapeutics (CMMB) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chemomab Therapeutics and its competitors. According to the industry distribution chart, Chemomab Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is Chemomab Therapeutics' EBITDA Margin % too high?
Chemomab Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Chemomab Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chemomab Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' EBITDA Margin % compare to HCWB and MTVA?
According to the Biotechnology industry distribution chart, Chemomab Therapeutics ranks #999999 out of 944 companies for EBITDA Margin %. This places Chemomab Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chemomab Therapeutics and its competitors. Chemomab Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Chemomab Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
33GF Score

Get the complete analysis for CMMB

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.59
Price